Results | The total number of postmarketing studies was 1841 in 2007 , 1901 in 2008 , 2227 in 2009 , 1774 in 2010 , and 1781 in 2011 . The total number of studies required under the FDAAA was 0 in 2007, 46 in 2008, 153 in 2009, 279 in 2010 , and 387 in 2011. There were 3 distinct trends in postmarketing studies during this period.
First, the number of studies not yet started decreased from 1044 (56.7%) in 2007 to 775 (43.5%) in 2011, whereas the number of studies required under the FDAAA but not yet started steadily increased each year since 2007 to 271 (15.2%) studies in 2011.
Second, there was an opposite trend for completed studies that fulfilled the postmarketing obligation, which increased from 122 (6.6%) in 2007 to 224 (12.6%) in 2011. There were no fulfilled FDAAA studies during this time.
Third, delayed studies increased from 125 (6.8%) in 2007 to 241 (13.5%) in 2011. By 2011, there were 19 studies required under the FDAAA that were delayed (1.1%).
Discussion | Because of heightened public scrutiny of the status of postmarketing studies, we expected uninitiated studies to decrease and fulfilled studies to increase since 2007. Indeed, our analysis found the number of studies not yet started declined during this 5-year period, and the number of studies fulfilling obligations nearly doubled. These trends Our investigation has limitations. First, it was not designed to statistically isolate the FDAAA's effect on fulfillment rates for postmarketing commitments. Second, our analysis does not examine the content and outcome of specific commitments because much of this information is not publicly available. Nevertheless, despite some gains in studies initiated and fulfilled, our analysis reinforces continued concerns about the status of prescription drug postmarketing studies in the United States. Most of these studies reported since 2007 were requested by the FDA before the FDAAA's enactment, which could explain the extent of delayed and unfulfilled studies during this period.
For those newer studies required under the FDAAA, which are steadily increasing each year, the FDA must enforce the law against companies failing to comply with study requirements. Under the FDAAA, the FDA can issue warning letters and initiate litigation for significant failures, including seizures and injunctions. These regulatory actions can help ensure the timely conduct and submission of adequate studies, which will ultimately strengthen the FDA's ongoing monitoring of prescription drug safety.
Pending: The study has not been initiated (ie, no patients have been enrolled or animals dosed), but does not meet the criterion for delayed (ie, the original projected date for initiation of patient accrual or initiation of animal dosing has not passed).
Ongoing: The study is proceeding according to, or is ahead of, the original schedule. The Food and Drug Administration (FDA) considers a study to be ongoing until a final study report is submitted to the FDA, as long as the activities are proceeding according to the original study schedule. If patient accrual or animal dosing has started but is not complete, and the projected date for completion of that milestone has passed, the study should be categorized as delayed.
Delayed: The progression of the study is behind the original study schedule. Delays can occur in any phase of the study, including patient enrollment, analysis of study results, or submission of the final study report to the FDA. Even though the original study schedule (not a revised schedule) serves as the basis for defining a study as delayed, each phase of the study will be considered in its own right. If the applicant has 1 delayed phase, but gets back on schedule during the next phase, the delayed status will no longer apply.
Terminated:
The applicant ended the study before completion, and
has not yet submitted a final study report to the FDA.
Submitted:
The applicant has concluded or terminated the study and has submitted a final study report to the FDA, but the FDA has not yet notified the applicant in writing that the study commitment has been fulfilled or that the commitment has been released.
Fulfilled:
The applicant has submitted the final study report for the commitment, and upon review of the final study report, the FDA is satisfied that the applicant has met the terms of the commitment.
Released:
The FDA has informed the applicant that it has been released from its obligation to conduct the postmarketing study because the study is either no longer feasible or would no longer provide useful information.
The fulfilled and released commitments will be displayed on the FDA website for not more than 1 year from the date the commitments are fulfilled or released. 
COMMENT & RESPONSE Aldosterone Inhibition in Patients With Heart Failure With Preserved Ejection Fraction
To the Editor The Aldosterone Receptor Blockade in Diastolic Heart Failure (Aldo-DHF) study 1 tested the hypothesis that aldosterone inhibition with spironolactone would result in improvement in maximum exercise capacity (peak V O 2 ) or diastolic function (E/e′), each a co-primary end point.
Whereas resting E/e′ was reduced by spironolactone, exercise capacity was not. The method of patient selection may have contributed to a false-negative result. We believe that this study illustrates the fundamental problems with the current concept of heart failure (HF) with preserved ejection fraction (EF) and, in particular, the role of exercise in this syndrome.
The definition of HF with preserved EF used by the investigators relied on the presence of breathlessness (New York Heart Association [NYHA] class >II), a preserved EF (>50%), and evidence of resting diastolic dysfunction (grade ≥1). Objective evidence of exercise limitation was necessary at baseline (via cardiopulmonary exercise testing) and resting spirometry was performed as a means to exclude those with respiratory limitation. Approximately half of the patients met diagnostic criteria of the European Society for Cardiology for HF with preserved EF, although the initiation of this study preceded the publication of these guidelines.
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Even though mean baseline peak V O 2 (16.4 mL/min/kg) indicated significant exercise limitation, the mean expired volume per unit time/volume of expired carbon dioxide (V E/ V CO 2 ) slope was 30.3. This implies that exercise limitation was not primarily cardiac in origin in approximately half of the patients. The V E/V CO 2 slope has physiological, diagnostic, and prognostic implications 3 ; a value of less than 30 is considered normal without adjustment for age and sex, whereas patients with HF typically far exceed this threshold. In this study, the normal mean V E/V CO 2 slope suggests that many of these patients may have been primarily deconditioned and that pathophysiological heterogeneity may have been a major confounder.
Heart failure with preserved EF should be considered a disorder in which therapeutic efficacy will primarily be seen in functional capacity. Phase 2 mechanistic trials are therefore likely to continue to use ergometric end points. However, the full physiological potential of cardiopulmonary exercise testing should be used to ensure a cardiac origin of limitation, 4 thus validating the diagnosis of HF with preserved EF and increasing study power. In contrast, current guidelines 2 emphasize resting echocardiographic indices, which are an insufficient basis on which to attribute a cardiac origin to dyspnea. If these fundamental issues are not addressed in trial methods, we believe negative findings will continue to predominate.
